Skip to search formSkip to main contentSkip to account menu

ZD 6021

Known as: (3-cyano-N-(2-(3,4-dichlorophenyl)-4-(4-(2-(methylsulfinyl)phenyl)piperidino)butyl)-N-methyl)naphthamide, ZD-6021, ZD6021 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

PiperidinesSulfoxides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3.
2008
2008
Occurrence and pharmacological characterization of four human tachykinin NK2 receptor variants.
Highly Cited
2007
Highly Cited
2007
Neurokinin 1 Receptor Antagonists: Correlation between in Vitro Receptor Interaction and in Vivo Efficacy
We compared the neurokinin 1 receptor (NK1R) antagonists aprepitant, CP-99994 [(2S,3S)-3-(2-methoxybenzylamino)-2… 
2007
2007
Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors.
2004
2004
Glutamate and tachykinin receptors in central sensitization of withdrawal reflexes in the decerebrated rabbit
This study assessed the involvement of NMDA and group I metabotropic glutamate receptors, and tachykinin NK1 and NK3 receptors… 
2002
2002
Design, synthesis, and SAR of tachykinin antagonists: modulation of balance in NK(1)/NK(2) receptor antagonist activity.
Through optimization of compounds based on the dual NK(1)/NK(2) antagonist ZD6021, it was found that alteration of two key… 
2001
2001
Discovery of novel, orally active dual NK1/NK2 antagonists.
2001
2001
Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
The tachykinins, substance P, neurokinin A, and neurokinin B, have been implicated in many diseases. The present study evaluated… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License